Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing dexlansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* infection. Dexlansoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. Amoxicillin and clarithromycin are antibiotics.
## Primary Indications
Eradication of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
The standard adult dose is one Sompraz HP packet taken orally twice daily for 10-14 days. Each packet typically contains dexlansoprazole 60 mg, amoxicillin 1000 mg, and clarithromycin 500 mg. The exact composition and duration may vary; consult local protocols and product labeling.
## Pediatric Dosing
Pediatric dosing is not established for this specific combination product. Dosing of individual components would be based on age, weight, and infection severity per specific guidelines.
## Dose Adjustments
No dose adjustments are typically required for renal or hepatic impairment for this combination product. However, individual components may have specific recommendations; refer to prescribing information for amoxicillin and clarithromycin.
## Contraindications
Hypersensitivity to dexlansoprazole, amoxicillin, clarithromycin, or other macrolides or penicillins. History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use. Concomitant use with ergotamines, cisapride, pimozide, or astemizole due to risk of serious cardiac arrhythmias.
## Adverse Effects
Common adverse effects include diarrhea, taste disturbances, nausea, abdominal pain, headache, and rash. Serious adverse effects can include hypersensitivity reactions, *Clostridioides difficile*-associated diarrhea, and QT prolongation (with clarithromycin).
## Key Drug Interactions
* **Dexlansoprazole:** May decrease the absorption of drugs requiring gastric acidity (e.g., ketoconazole, itraconazole, iron salts). May increase the absorption of CYP3A4 substrates (e.g., cyclosporine).
* **Amoxicillin:** May decrease the efficacy of oral contraceptives. Probenecid can decrease renal excretion of amoxicillin.
* **Clarithromycin:** Potent inhibitor of CYP3A4. Significant interactions with statins (risk of myopathy), colchicine (risk of toxicity), certain anticoagulants (e.g., warfarin), antiarrhythmics (e.g., digoxin, quinidine), and CNS depressants.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for diarrhea, especially if severe or persistent, to rule out *C. difficile*-associated diarrhea.
* Assess for therapeutic response (e.g., resolution of ulcer symptoms, confirmation of *H. pylori* eradication via breath test or stool antigen test).
* Monitor for adverse effects of individual components, particularly QT interval with clarithromycin if risk factors are present.
## Clinical Pearls
* Administer the entire contents of the packet twice daily.
* Ensure completion of the full 10-14 day course to maximize eradication rates and minimize resistance development.
* Advise patients to report any severe or persistent diarrhea, rash, or signs of allergic reaction immediately.
* Consider alternative antibiotic therapy in patients with penicillin allergy or known macrolide resistance.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
